Clinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach
CONCLUSIONS: PAD interventionalists practicing at an academic health system recognize the heterogenous response of their patients to clopidogrel therapy but are unsure when to leverage genetic testing to improve outcomes for their patients. Our study identified gaps regarding PAD interventionalists' knowledge, perceived barriers, and attitudes toward CYP2C19 testing in PAD. This information highlights the need for randomized data on genetic testing for clopidogrel responsiveness in peripheral vascular disease following intervention to help guide antiplatelet management.PMID:38669051 | DOI:10.1177/17085381241246318 (Source: Vascular)
Source: Vascular - April 26, 2024 Category: Surgery Authors: Christopher Regan Lindsey E Scierka Alan Dardik Britt Tonnessen Cassius Iyad Ochoa Chaar Costin Ionescu Edouard Aboian Jonathan Cardella Naiem Nassiri Raul Guzman Robert Attaran Sameer Nagpal Samit Shah Kim G Smolderen Carlos Mena-Hurtado Source Type: research
Recommendations for pharmacogenetic testing in clinical practice guidelines in the US
CONCLUSION: A standardized approach to evaluating the evidence of clinical utility for pharmacogenetic testing may increase the inclusion and consistency of pharmacogenetic testing recommendations in clinical practice guidelines, which could benefit patients and society by increasing clinical use of pharmacogenetic testing.PMID:38652504 | DOI:10.1093/ajhp/zxae110 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - April 23, 2024 Category: Drugs & Pharmacology Authors: Daniel L Hertz Chad A Bousman Howard L McLeod Andrew A Monte Deepak Voora Lori A Orlando Rustin D Crutchley Benjamin Brown Wrenda Teeple Sara Rogers Jai N Patel Source Type: research
Recommendations for pharmacogenetic testing in clinical practice guidelines in the US
CONCLUSION: A standardized approach to evaluating the evidence of clinical utility for pharmacogenetic testing may increase the inclusion and consistency of pharmacogenetic testing recommendations in clinical practice guidelines, which could benefit patients and society by increasing clinical use of pharmacogenetic testing.PMID:38652504 | DOI:10.1093/ajhp/zxae110 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - April 23, 2024 Category: Drugs & Pharmacology Authors: Daniel L Hertz Chad A Bousman Howard L McLeod Andrew A Monte Deepak Voora Lori A Orlando Rustin D Crutchley Benjamin Brown Wrenda Teeple Sara Rogers Jai N Patel Source Type: research
Dual-pathway inhibition in patients with chronic limb-threatening ischemia requiring reintervention for infrapopliteal occlusions
AbstractOur study aimed to assess the influence of incorporating new oral anticoagulant (NOAC) therapy on clinical outcomes among patients who underwent endovascular intervention for below-the-knee (BTK) occlusions necessitating reintervention. The inclusion criteria encompassed patients with chronic limb-threatening ischemia (CLTI) and had undergone a successful endovascular intervention for BTK artery occlusion, necessitating reintervention. Patients who underwent endovascular interventions for BTK reocclusion were compared to those who received dual-pathway inhibition with NOAC (rivaroxaban 2.5 mg 2 × 1) and clop...
Source: Heart and Vessels - April 22, 2024 Category: Cardiology Source Type: research
Preoperative aspirin and anticoagulants do not affect partial nephrectomy bleeding
CONCLUSIONS: No difference in complication rate of partial nephrectomy was determined to be solely due to prior use of anticoagulation or aspirin use alone with appropriate cessation of anticoagulation preoperatively. Overall, patients on anticoagulation are not at a higher risk of intraoperative or postoperative bleeding complications when undergoing partial nephrectomy.PMID:38642461 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - April 20, 2024 Category: Urology & Nephrology Authors: Muqsit Buchh Courtney Yong Fezaan Kazi Ali Sualeh James Slaven Ronald S Boris Chandru P Sundaram Source Type: research
Investigation of smoking on the antiplatelet response to clopidogrel: Unravelling the smoker's paradox
Pathol Res Pract. 2024 Apr 10;257:155290. doi: 10.1016/j.prp.2024.155290. Online ahead of print.ABSTRACTThe intricate relationship between smoking and the effects of the antiplatelet drug clopidogrel has been termed the "smoker's paradox". This paradox details the enhanced efficacy of clopidogrel in smokers compared to non-smokers. This review begins with an exploration of the proposed mechanisms of the smoker's paradox, particularly drawing attention to the induction of cytochrome P450 (CYP) isoenzymes via tobacco smoke, specifically the enzymes CYP1A2 and CYP2C19. Moreover, an investigation of the effects of genetic vari...
Source: Pathology, Research and Practice - April 19, 2024 Category: Pathology Authors: Frank A Plakogiannis Jakob Weidmann Blake Fraser Justin Kwong Diana Asi Pratham Kumar Madeleine Baldock Jasmine Naamo Ruhani Baluja Rachelle Catanzariti Stewart Yeung Lisa Pont Kylie Williams Gabriele De Rubis Kamal Dua Nadeem Irfan Bukhari Source Type: research
Ticagrelor downregulates the expression of proatherogenic and proinflammatory miR125-b compared to clopidogrel: A randomized, controlled trial
Platelet P2Y12 antagonist ticagrelor reduces cardiovascular mortality after acute myocardial infarction (AMI) compared to clopidogrel, but the underlying mechanism is unknown. Because activated platelets release proatherogenic and proinflammatory microRNAs, including miR-125a, miR-125b and miR-223, we hypothesized that the expression of these miRNAs is lower on ticagrelor, compared to clopidogrel. (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - April 19, 2024 Category: Cardiology Authors: Aleksandra Gasecka, Ewelina B łażejowska, Kinga Pluta, Magdalena Gajewska, Sylwester Rogula, Krzysztof J. Filipiak, Janusz Kochman, Jolanta M. Siller-Matula, Marek Postuła, Ceren Eyileten Source Type: research
Comparative effectiveness and safety of ticagrelor and clopidogrel in patients with or without chronic liver disease: a nationwide cohort study
Although the effectiveness and safety of ticagrelor versus clopidogrel may differ in patients with chronic liver disease, there is a scarcity of evidence comparing ticagrelor and clopidogrel in patients with chronic liver disease. We aimed to evaluate the risk of major adverse cardiovascular events (MACE) and major bleeding associated with ticagrelor versus clopidogrel in patients undergoing percutaneous coronary intervention (PCI) due to acute coronary syndrome by chronic liver disease status. (Source: The American Journal of Medicine)
Source: The American Journal of Medicine - April 17, 2024 Category: General Medicine Authors: Bin Hong, Sungho Bea, Seng Chan You, Yoosoo Chang, Won Kim, Ju-Young Shin Tags: Clinical Research Study Source Type: research
Ticagrelor vs clopidogrel when coadministered with bivalirudin in patients with acute coronary syndrome undergoing percutaneous coronary intervention
CONCLUSION: As an initial treatment strategy, bivalirudin plus ticagrelor could reduce the 12-month risk of ischemic events compared with bivalirudin plus clopidogrel significantly without increasing the bleeding risk in ACS patients undergoing PCI.PMID:38623472 | PMC:PMC11017352 | DOI:10.1016/j.rpth.2024.102375 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - April 16, 2024 Category: Hematology Authors: Yang Li Yi Li Miaohan Qiu Yu Xue Kai Xu Yaling Han Source Type: research
Ticagrelor vs clopidogrel when coadministered with bivalirudin in patients with acute coronary syndrome undergoing percutaneous coronary intervention
CONCLUSION: As an initial treatment strategy, bivalirudin plus ticagrelor could reduce the 12-month risk of ischemic events compared with bivalirudin plus clopidogrel significantly without increasing the bleeding risk in ACS patients undergoing PCI.PMID:38623472 | PMC:PMC11017352 | DOI:10.1016/j.rpth.2024.102375 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - April 16, 2024 Category: Hematology Authors: Yang Li Yi Li Miaohan Qiu Yu Xue Kai Xu Yaling Han Source Type: research
Ticagrelor Versus Clopidogrel in Acute Large-Vessel Ischemic Stroke: A Randomized Controlled Single-Blinded Trial
ConclusionPatients with acute large-vessel ischemic stroke who received ticagrelor within the first 24 hours after ischemic stroke had better clinical outcomes based on recurrent stroke rates, NIHSS reduction, and favorable mRS rates compared with those who received clopidogrel. There were no differences between ticagrelor and clopidogrel regarding hemorrhagic and non-hemorrhagic complications.Trial RegistrationClinical trials.gov (NCT06120725). (Source: CNS Drugs)
Source: CNS Drugs - April 15, 2024 Category: Neurology Source Type: research
Feasibility and Safety of Bridging Antiplatelet Therapy with Cangrelor in Neuro-Oncology: A Preliminary Experience
J Neurol Surg A Cent Eur Neurosurg DOI: 10.1055/s-0044-1785649Antiplatelet therapy is mandatory for prevention of thrombotic events in patients with a recent history of acute coronary syndromes and/or percutaneous coronary interventions. However, if an urgent surgery is required during antiplatelet therapy, a compromise between the ischemic/thrombotic and hemorrhagic risk has to be reached. Different bridging schemes are reported in the literature, but there is no clear consensus on the optimal treatment strategy in terms of efficacy and safety. Although some indications about the perioperative management of antiplatelet t...
Source: Journal of Neurological Surgery Part A: Central European Neurosurgery - April 15, 2024 Category: Neurosurgery Authors: Bertolini, Giacomo Belli, Laura Mazza, Stefania Ugolotti, Pietro Tito Tadonio, Iacopo Ceccarelli, Patrizia Rossi, Sandra Ippolito, Salvatore Tags: Technical Note Source Type: research
Influence of sex on the timing of coronary angiography and the prescription of antiplatelet therapy in patients with nonST-segment elevation myocardial infarction
CONCLUSION: Women were more often prescribed less potent antithrombotic therapy than men. Frailty, but not sex, correlated independently with deferral of coronary angiography. However, we detected no differences in the frequency of coronary revascularization or in-hospital events according to sex.PMID:38597619 | DOI:10.55633/s3me/016.2024 (Source: Atherosclerosis)
Source: Atherosclerosis - April 10, 2024 Category: Cardiology Authors: Antonio Mart ínez-Guisado Pedro Cepas-Guill én Pablo D íez-Villanueva Mar ía Thiscal López Lluva Alfonso Jurado-Rom án Pablo Bazal-Chac ón Mart ín Negreira-Caamaño Iv án Olavarri-Miguel Ane Elorriaga Ricardo Rivera-L ópez David Escribano Pablo Source Type: research
Influence of sex on the timing of coronary angiography and the prescription of antiplatelet therapy in patients with nonST-segment elevation myocardial infarction
CONCLUSION: Women were more often prescribed less potent antithrombotic therapy than men. Frailty, but not sex, correlated independently with deferral of coronary angiography. However, we detected no differences in the frequency of coronary revascularization or in-hospital events according to sex.PMID:38597619 | DOI:10.55633/s3me/016.2024 (Source: Atherosclerosis)
Source: Atherosclerosis - April 10, 2024 Category: Cardiology Authors: Antonio Mart ínez-Guisado Pedro Cepas-Guill én Pablo D íez-Villanueva Mar ía Thiscal López Lluva Alfonso Jurado-Rom án Pablo Bazal-Chac ón Mart ín Negreira-Caamaño Iv án Olavarri-Miguel Ane Elorriaga Ricardo Rivera-L ópez David Escribano Pablo Source Type: research
